

Form PTO-1449 (modified)	Atty. Docket No.: EPL:015US	Serial No.: 10/599,937
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant: Anna CEDERHOLM Johan FROSTEGÅRD	
	Filing Date: August 21, 2007	Group: 1644
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-2</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
/SW/	B12	EP 1 411 134	04/21/04	WIPO	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/SW/	C44	Blanco-Colio <i>et al.</i> , "3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation," <i>Atherosclerosis</i> , 161:17-26, 2002.
	C45	Chen <i>et al.</i> , "Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants," <i>Blood</i> , 105:3902-3909, 2005.
	C46	De Winther <i>et al.</i> , "Macrophage scavenger receptor class A: A multifunctional receptor in atherosclerosis," <i>Arterioscler. Thromb. Vasc. Biol.</i> , 20:290-297, 2008.
	C47	Ferri <i>et al.</i> , "Early upregulation of endothelial adhesion molecules in obese hypertensive men," <i>Hypertension</i> , 34:568-573, 2008.
	C48	Fitzgerald, "Vascular biology of thrombosis," <i>Neurology</i> , suppl. 2:S1-S3, 2001.
	C49	Gomberg-Maitland <i>et al.</i> , "Statins and plaque stability," <i>J. Cardiovas. Risk</i> , 10:161-167, 2003.
	C50	Hofstra <i>et al.</i> , "Visualisation of cell death in vivo in patients with acute myocardial infarction," <i>The Lancet</i> , 356:209-212, 2000.
	C51	Kaneta <i>et al.</i> , "All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells," <i>Atherosclerosis</i> , 170:237-243, 2003.
	C52	Kemerink <i>et al.</i> , "Patient dosimetry of intravenously administered 99mTc-annexin V," <i>J. Nucl. Med.</i> , 42:382-387, 2001.

65453386.1

EXAMINER: /Sharon Wen/

DATE CONSIDERED: 04/20/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: EPCL:015US	Serial No.: 10/599,937
List of Patents and Publications for Applicant's		Applicant: Anna CEDERHOLM Johan FROSTEGÅRD	
INFORMATION DISCLOSURE STATEMENT		Filing Date: August 21, 2007	Group: 1644
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-2</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/SWI/	C53	Kolodgie <i>et al.</i> , "Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death," <i>Am. J. Pathol.</i> , 157:1259-1268, 2000.
	C54	Kolodgie <i>et al.</i> , "Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: a technique with potential for noninvasive imaging of vulnerable plaque," <i>Circulation</i> , 108(25):3134-9, 2003.
	C55	Loftus <i>et al.</i> , "Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption," <i>Stroke</i> , 31:40-47, 2000.
	C56	Lugens <i>et al.</i> , "Atherosclerotic plaque rupture: local or systemic process?," <i>Arterioscler. Thromb. Vasc. Biol.</i> , 23:2123-2130, 2003.
	C57	Medicine Abstract, NLM12611042, "The vulnerable plaque: a necessary concept in the management of atherothrombosis," by Rioufol and Finet, <i>Archives des maladies du coeur et des vaisseaux</i> , 95:1210-1214, 2002.
	C58	Meir & Leitersdorf, "Atherosclerosis in the apolipoprotein E-deficient mouse: A decade of progress," <i>Arterioscler. Thromb. Vasc. Bio.</i> , 24:1006-1014, 14 May 2007 and 6 August 2007.
	C59	Prescott, "Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury," <i>Ann. NY Acad. Sci.</i> , 30:179-190, 2008.
	C60	Son, "Effects of statin in plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease," <i>Int. J. Cardiol.</i> , 88:77-82, 2008.
	C61	Viles-Gonzalez <i>et al.</i> , "Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences," <i>European Heart Journal</i> , 25:1197-1207, 2004.
	C62	Zhou <i>et al.</i> , "Dietary supplementation with methionine and homocysteine promotes early atherosclerosis but not plaque rupture in ApoE-deficient mice," <i>Arterioscler. Thromb. Vasc. Biol.</i> , 21:1470-1476, 2001.

65453386.1

EXAMINER:	/Sharon Wen/	DATE CONSIDERED:	04/20/2010
-----------	--------------	------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.